RT @AurelieRheumo: New benefit/risk outlook ð on ORAL surveillance 2 subgrps: ð¢RA w/ no previous Hx of atheroscler
Tweet Content
New benefit/risk outlook 👀 on ORAL surveillance
2 subgrps:
🟢RA w/ no previous Hx of atherosclerotic CV dis = TOFA at least as good as TNFi
AND risk of MACE is comparable 🛑RA w/ HxASCVD = efficacy TOFA = TNFi AND > risk of MACE
https://t.co/VOxNQSoyY4 OP0043 #EULAR23 @Rheumnow https://t.co/m98eSMG03U
Links
EULAR Abstract Archive
http://bit.ly/42mst6w
Show on Archive Page
On
Display in Search Results
On
PDQ
Off